Benchmark Steps to Sidelines on Repligen (RGEN), 'Shares Reach Price Target'
Tweet Send to a Friend
Benchmark analyst Robert Wasserman downgraded Repligen (NASDAQ: RGEN) from Buy to Hold.The analyst comments "We are lowering our rating on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
